WCM Investment Management LLC Grows Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

WCM Investment Management LLC raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 125.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 135,754 shares of the company's stock after acquiring an additional 75,584 shares during the period. WCM Investment Management LLC's holdings in Teva Pharmaceutical Industries were worth $3,030,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UMB Bank n.a. boosted its stake in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares during the period. Smithfield Trust Co boosted its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $52,000. Finally, Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $66,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.25 during trading on Thursday, hitting $16.59. The stock had a trading volume of 11,072,147 shares, compared to its average volume of 12,934,726. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. The firm has a market capitalization of $18.79 billion, a P/E ratio of -11.44, a PEG ratio of 1.39 and a beta of 0.71. The company's 50-day moving average price is $20.01 and its 200 day moving average price is $18.50. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TEVA shares. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Finally, Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.